Keywords: indaflex, misses, ph, ii, endpoints, canada, alpharx
Indaflex misses Ph II endpoints
Article | 21 May 2007
Canada's AlphaRx and USA-based Proprius Pharmaceuticals say that their co-developed topical non-steroidal anti-infalmmatory Indaflex (2.5% indomethacin cream) missed its primary endpoint ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
